OncoAlert 4Sight Abstracts to be Presented at #ESMO26
BRIDGET: A Phase II Trial of Tucatinib Added to Trastuzumab/Pertuzumab or Ado-Trastuzumab Emtansine After Isolated Intracranial Progression in Patients With Advanced HER2-Positive Breast Cancer

@drsarahsam
@DrVanSwearingen
@rashmikmurthy
@CareyAnders1

🔬 Single-arm phase II (47 evaluable): tucatinib added to ongoing HP or T-DM1 after SRS for isolated intracranial progression in HER2+ MBC. Primary endpoint: iPFS (RANO-BM).
➡️ Median iPFS not reached; p<0.0001 vs historical median of 5 mo
➡️ iPFS 91% at 6 mo, 64% at 12 mo, 59% at 18 mo
➡️ Grade ≥3 AEs 15%; extracranial progression 4.3%
✅ Adding tucatinib to HP after radiation met the primary endpoint, with more than half of patients free of intracranial progression at 18 months. #BreastCancer

🎙️ Sarah Sammons
👥 Amanda Van Swearingen · Laura Noteware · Nusayba Bagegni · Kelly Moulton · Stevie Threatt · Denise Jaggers · Shannon Shea · Eric Lipp · Erin Riley · Sin-Ho Jung · Gloria Broadwater · Masey Ross · Kimberly Strickland · Sasha Beyer · Alison Conlin · Aki Morikawa · Rashmi Murthy · Carey Anders

(4Sight Made from Abstracts publicly available at the ESMO website)

Pinging OncoAlert Breast Cancer Faculty
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc
@Lucarecco @Dr_Oncologista @guiandri76